for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zymeworks Inc

ZYME.TO

Latest Trade

36.25CAD

Change

1.59(+4.59%)

Volume

12,353

Today's Range

34.80

 - 

36.55

52 Week Range

14.34

 - 

39.10

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
34.66
Open
34.80
Volume
12,353
3M AVG Volume
5.80
Today's High
36.55
Today's Low
34.80
52 Week High
39.10
52 Week Low
14.34
Shares Out (MIL)
39.26
Market Cap (MIL)
1,077.29
Forward P/E
-10.21
Dividend (Yield %)
--

Latest Developments

More

Zymeworks Announces New Chair Of Board Of Directors And Voluntary Delisting From The TSX

Zymeworks Posts Q2 Loss Per Share Of $0.89

Zymeworks Files Preliminary Prospectus Supplements For Offering Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zymeworks Inc

Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.

Industry

Biotechnology & Drugs

Contact Info

540-1385 West 8Th Avenue

+1.604.6781388

Key Stats

1.44 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2017

-2.600

2018

-1.260

2019(E)

-2.525
Price To Earnings (TTM)
--
Price To Sales (TTM)
21.21
Price To Book (MRQ)
3.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
-18.59
Return on Equity (TTM)
-16.69

Latest News

BRIEF-Zymeworks Files For Mixed Shelf Of Upto $250 Mln - SEC Filing

* ZYMEWORKS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: [https://bit.ly/2w8uM3f] Further company coverage:

BRIEF-Zymeworks Inc - QTRLY Loss Per Share $0.83

* ZYMEWORKS INC - REVENUE FOR THREE MONTHS ENDED MARCH 31, 2018 WAS $0.04 MILLION AS COMPARED TO $0.23 MILLION IN SAME PERIOD IN 2017

BRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration

* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION

BRIEF-Zymeworks Reports Qtrly Net Income Per Common Share $1.29

* ZYMEWORKS INC - QTRLY RESEARCH AND DEVELOPMENTAL COLLABORATIONS REVENUE $50.1 MILLION

BRIEF-Zymeworks Adds New Clinical Sites In Canada And U.S. For Ongoing Study

* ZYMEWORKS - ADDS NEW CLINICAL SITES IN CANADA AND U.S. FOR ONGOING ADAPTIVE PHASE 1 STUDY OF CO'S LEAD CLINICAL CANDIDATE, ZW25 Source text for Eikon: Further company coverage:

BRIEF-BDC Capital Reports 7.58 Pct Passive Stake In Zymeworks

* BDC CAPITAL INC REPORTS 7.58 PERCENT PASSIVE STAKE IN ZYMEWORKS INC AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2nZkV9s) Further company coverage:

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation

* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics

BRIEF-Zymeworks reports third quarter loss of $0.65 per share

* Zymeworks reports third quarter 2017 financial results and provides business update

BRIEF-Zymeworks presents additional safety and anti-tumor activity data from ongoing phase 1 study of ZW25

* Zymeworks presents additional safety and anti-tumor activity data from the ongoing phase 1 study of zw25 at the european society for medical oncology 2017 congress (“ESMO”)

BRIEF-Zymeworks reports second quarter financial results

* Zymeworks Inc says net loss for three months ended June 30, 2017 was $11.0 million

BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

* Zymeworks - two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

* Zymeworks - two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

BRIEF-Celgene Alpine Investment reports 6.2 pct stake in Zymeworks Inc

* Celgene Alpine Investment Co Llc reports 6.2 percent passive stake in Zymeworks Inc as on May 3, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2q8uAND) Further company coverage: [Zymeworks Inc]

BRIEF-Zymeworks prices IPO of 4.5 mln common shares at $13/shr

* Pricing of its initial public offering of 4.5 million common shares at a price to public of U.S.$13.00 per share Source text for Eikon: Further company coverage:

BRIEF-Zymeworks Inc sees IPO of up to 4.5 million common shares

* Zymeworks Inc sees IPO of up to 4.5 million common shares - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up